Could Gilead Make A Profit From Remdesivir?
Roche’s Tamiflu Was A Pandemic Blockbuster, But COVID-19 Is Different
All being well, Gilead could gain emergency approval for remdesivir by early May - but arriving at a 'reasonable' price and devising rapid access programs will be a major challenge.
You may also be interested in...
Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.